Argenx stock projected to rise 23% on biotech momentum

Argenx is experiencing significant business momentum, with Wall Street analysts projecting a potential 23% upside for its stock over the next 12 months. The biotech company has reported 18 consecutive quarters of revenue growth, including a 60% year-over-year increase in global product net sales to $1.5 billion in the second quarter of 2026.

A primary driver for this growth is the Vyvgart franchise, which treats chronic autoimmune disorders such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's growth was bolstered by a May 2026 FDA label expansion, making Vyvgart and Vyvgart Hytrulo the first and only approved treatments for all serotypes of adults with gMG.